Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

被引：1
|
作者：
Rueda, Antonio [1 ]
Calvo, Virginia [2 ]
Casanova, Maria [1 ]
Rodriguez-Abreu, Delvys [3 ]
Aguiar, David [4 ]
Llanos, Marta [5 ]
Alvarez, Ruth [6 ]
Martinez-Banaclocha, Natividad [7 ]
Alfaro, Jesus [8 ]
Quero, Cristina [9 ]
Blasco, Ana [10 ]
de la Cruz Merino, Luis [11 ]
Herrero, Joaquin [12 ]
Garcia-Arroyo, Francisco R. [13 ]
Provencio, Mariano [2 ]
机构：
[1] Hosp Costa Sol, Marbella, Spain
[2] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
[3] Hosp Insular, Las Palmas Gran Canaria, Las Palmas, Spain
[4] Hosp Dr Negrin, Las Palmas Gran Canaria, Las Palmas, Spain
[5] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[6] Hosp Virgen Salud, Toledo, Spain
[7] Hosp Gen Univ Elche, Alicante, Spain
[8] Oncologikoa, Donostia San Sebastian, Spain
[9] Hosp Univ Gen & Virgen Victoria, Malaga, Spain
[10] Hosp Gen Univ, Valencia, Spain
[11] Hosp Virgen Macarena, Seville, Spain
[12] Hosp Gen Univ Alicante, Alicante, Spain
[13] Complexo Hosp Univ Pontevedra, Pontevedra, Spain
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 06期
关键词：
NON-HODGKIN-LYMPHOMA; INDOLENT B-CELL; PLUS RITUXIMAB; MANTLE-CELL; 1ST-LINE TREATMENT; OPEN-LABEL; RELAPSED INDOLENT; MULTICENTER; OBINUTUZUMAB; THERAPY;
D O I：
10.1080/10428194.2018.1542147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1576 / 1579
页数：4
相关论文
共 30 条
  • [21] Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
    Ogura, Michinori
    Sancho, Juan Manuel
    Cho, Seok-Goo
    Nakazawa, Hideyuki
    Suzumiya, Junji
    Tumyan, Gayane
    Kim, Jin Seok
    Lennard, Anne
    Mariz, Jose
    Ilyin, Nikolai
    Jurczak, Wojciech
    Martinez, Aurelio Lopez
    Samoilova, Olga
    Zhavrid, Edvard
    Ruiz, Eduardo Yanez
    Trneny, Marek
    Popplewell, Leslie
    Coiffier, Bertrand
    Buske, Christian
    Kim, Woo-Seog
    Lee, Sang Joon
    Lee, Sung Young
    Bae, Yun Ju
    Kwak, Larry W.
    LANCET HAEMATOLOGY, 2018, 5 (11): : E543 - E553
  • [22] Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD plus C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS
    Houot, R.
    Le Gouill, S.
    Uribe, M. Ojeda
    Mounier, C.
    Courby, S.
    Dartigeas, C.
    Bouabdallah, K.
    Vigier, M. Alexis
    Moles, M. P.
    Tournilhac, O.
    Arakelyan, N.
    Rodon, P.
    El Yamani, A.
    Sutton, L.
    Fornecker, L.
    Assouline, D.
    Harousseau, J. L.
    Maisonneuve, H.
    Caulet-Maugendre, S.
    Gressin, R.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1555 - 1561
  • [23] Brief-Duration Rituximab/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research Consortium
    Hainsworth, John D.
    Flinn, Ian W.
    Spigel, David R.
    Clark, Bobby L.
    Griner, Paula L.
    Vazquez, Elizabeth R.
    Doss, Habib H.
    Shipley, Dianna
    Franco, Luis A.
    Burris, Howard A., III
    Greco, F. Anthony
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 44 - 50
  • [24] Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial
    Koutras, Angelos
    Zagouri, Flora
    Koliou, Georgia-Angeliki
    Psoma, Elizabeth
    Chryssogonidis, Ioannis
    Lazaridis, Georgios
    Tryfonopoulos, Dimitrios
    Kotsakis, Athanasios
    Res, Eleni
    Kentepozidis, Nikolaos K.
    Razis, Evangelia
    Psyrri, Amanda
    Koumakis, Georgios
    Kalofonos, Haralabos P.
    Dimopoulos, Meletios A.
    Fountzilas, George
    BRITISH JOURNAL OF CANCER, 2020, 123 (03) : 355 - 361
  • [25] Efficacy fi cacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801)
    Shi, Yuankai
    Chen, Gongyan
    Zhao, Yanqiu
    Zhao, Jing
    Lin, Lin
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (02): : 103 - 111
  • [26] Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy
    Martinez, Carmen
    Diaz-Lopez, Antonio
    Rodriguez-Calvillo, Mercedes
    Garcia-Sanz, Ramon
    Jose Terol, Maria
    Perez-Ceballos, Elena
    Jimenez, Maria J.
    Cantalapiedra, Alberto
    Domingo-Domenech, Eva
    Jose Rodriguez, Maria
    Sampol, Antonia
    Espeso, Manuel
    Lopez, Francisco-Javier
    Briones, Javier
    Garcia, Juan F.
    Sureda, Anna
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (06) : 859 - 867
  • [27] Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi
    Storti, Sergio
    Spina, Michele
    Pesce, Emanuela Anna
    Salvi, Flavia
    Merli, Michele
    Ruffini, Alessia
    Cabras, Giuseppina
    Chiappella, Annalisa
    Angelucci, Emanuele
    Fabbri, Alberto
    Liberati, Anna Marina
    Tani, Monica
    Musuraca, Gerardo
    Molinari, Annalia
    Petrilli, Maria Pia
    Palladino, Carmela
    Ciancia, Rosanna
    Ferrario, Andrea
    Gasbarrino, Cristiana
    Monaco, Federico
    Fraticelli, Vincenzo
    De Vellis, Annalisa
    Merli, Francesco
    Luminari, Stefano
    HAEMATOLOGICA, 2018, 103 (08) : 1345 - 1350
  • [28] Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
    Kim, Won Seog
    Buske, Christian
    Ogura, Michinori
    Jurczak, Wojciech
    Sancho, Juan-Manuel
    Zhavrid, Edvard
    Kim, Jin Seok
    Hernandez-Rivas, Jose-Angel
    Prokharau, Aliaksandr
    Vasilica, Mariana
    Nagarkar, Rajinish
    Osmanov, Dzhelil
    Kwak, Larry W.
    Lee, Sang Joon
    Lee, Sung Young
    Bae, Yun Ju
    Coiffier, Bertrand
    LANCET HAEMATOLOGY, 2017, 4 (08): : E362 - E373
  • [29] Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
    De Angelis, C.
    Bruzzese, D.
    Bernardo, A.
    Baldini, E.
    Leo, L.
    Fabi, A.
    Gamucci, T.
    De Placido, P.
    Poggio, F.
    Russo, S.
    Forestieri, V
    Lauria, R.
    De Santo, I
    Michelotti, A.
    Del Mastro, L.
    De Laurentiis, M.
    Giuliano, M.
    De Placido, S.
    Arpino, G.
    ESMO OPEN, 2021, 6 (02)
  • [30] A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial
    Grunenberg, Alexander
    Kaiser, Lisa M.
    Woelfle, Stephanie
    Schmelzle, Birgit
    Viardot, Andreas
    Moeller, Peter
    Barth, Thomas F. E.
    Muche, Rainer
    Dreyhaupt, Jens
    Raderer, Markus
    Kiesewetter, Barbara
    Buske, Christian
    BMC CANCER, 2021, 21 (01)
123